HBM Healthcare Investments Ltd Access to a Global and Diversified Private Equity Healthcare Portfolio SECA conference Zurich, 3 July 2013 Dr. Andreas Wicki, CEO
HBM at a Glance SIX-listed investment company (Ticker: HBMN SW Equity) Net assets (NAV) Market capitalisation CHF 670 million CHF 543 million NAV per share CHF 76.73 Share price CHF 59.00 Discount 23.1% Number of issued shares Number of shareholders 700 9.2 million Performance Share price since 1 Jan 13 (YTD) +27.2% 2012 +16.1% NAV since 1 Jan 13 (YTD) +30.4% 2012 +3.2% Charts as at 31 May 2013 (since first listing on SIX Swiss Exchange on 14 Feb 2008); indexed (12.7.2001 = 100) CHF 120 100 80 60 40 20 0 USD 180 160 140 120 100 80 60 40 20 0 HBM NAV page 2 HBM Share price MSCI World Health Care Index HBM NAV HBM Share price MSCI World Health Care Index
A Global Healthcare Portfolio page 3 ChemoCentryx Intervent. Spine Ellipse Tensys Pacira Enanta PTC Ophthotech SkyePharma Basilea Swedish Orphan Probiodrug Nabriva Medimpulse Cathay Private companies Public companies 15 largest direct investments
Largest Investments (1/2) Company Main business Infectious diseases (Antiinfectives) Phase of Lead Product Ticker Market Capitalisation (CHF m) Ownership in % Book value (CHF m) page 4 In % of NAV Phase III BSLN 688 <25.0 149,1 22,2 Injectable medicines with (patented) controlled release of active drug Back-of-the-eye diseases, focusing on macular degeneration (AMD) Long chain diacids, carbohydrates and special enzymes Infectious diseases (Hepatitis C) Autoimmune diseases, inflammatory disorders and cancer Market PCRX 923 6,5 59,8 8,9 Phase III Private 298 1) 13,5 40,3 6,0 Markt Private 212 1) 12,6 26,7 4,0 Phase III ENTA 332 7,8 26,0 3,9 Phase III CCXI 540 4,4 24,3 3,6 As at 31 May 2013 (FX USD/CHF: 0.9551, FX EUR/CHF: 1.2415) 1) For private companies: Implied company valuation
Largest Investments (2/2) Company Main business Phase of Lead Product Ticker Market Capitalisation (CHF m) Ownership in % Book value (CHF m) page 5 In % of NAV Genetic diseases Phase III Private 172 1) 12,3 21,1 3,1 Serious skin infections and bacterial pneumonia Phase II Private 136 1) 11,9 16,2 2,4 Minimally invasive spinal implants Drug delivery for oral and inhalation products Market Private 52 1) 31,4 16,2 2,4 Market SKP 34 23,8 16,2 2) 2,4 Hemodynamic patient monitoring Market Private 10 1) 100,0 9,9 1,5 Products for treatment of rare diseases Market SOBI 1 571 0,5 8,3 1,2 As at 31 May 2013 (FX USD/CHF: 0.9551, FX EUR/CHF: 1.2415) 1) For private companies: Implied company valuation 2) Shares and Bond
Pacira Pharmaceuticals The EXPAREL Growth Story page 6 Share price since IPO on 3 Feb 2011 (in USD) Quarterly sales of Exparel (in million USD) x 4.2 Data as at 31 May 2013 Market cap USD 967m Enterprise value USD 953m Book value HBM USD 63m Ownership 6.5% Analyst consensus estimates for annual sales Multiple on invested capital of 2.7x
Pacira Pharmaceuticals HBM is an Active long-term Shareholder First investment of HBM in syndicate with MPM Capital, OrbiMed Advisors LLC and Sanderling Ventures Strengthening of management team and board representation March 07 Established as spin-out of the Skye Pharma Injectable Business Further investments 2008-10 Oct / Dec 09 Phase III studies reached primary endpoint Actively involved in strategic discussions, business development and IPO preparation Dec 10 NDA acceptance by the FDA Further investments at IPO and follow-on Feb 11 IPO on the NASDAQ Okt. 11 EXPAREL received US market approval from the FDA for the treatment of post-operative pain April 12 - Commercial rollout of EXPAREL in the US; reported clinical data suggests label expansion into other high growing sectors page 7
Why Invest in HBM Healthcare Investments? page 8 Invested in emerging therapies: Orphan and infectious diseases, Hep C and wet AMD Near-term value inflection points Balanced and diversified portfolio of de-risked late stage assets and growth companies both private and public Long-term expertise of investing in private and public companies Actively managed investment positions Committed to Shareholders Share buy-back and cash distribution
Contact page 9 HBM Healthcare Investments Ltd Bundesplatz 1 CH-6300 Zug Switzerland Phone +41 41 768 11 08 Fax +41 41 768 11 09 info@hbmhealthcare.com www.hbmhealthcare.com
Disclaimer page 10 Cautionary Statement This presentation contains forward-looking statements based on the currently held beliefs and assumptions of the management of HBM Healthcare Investments Ltd, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of HBM Healthcare Investments Ltd, or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this presentation are cautioned not to place undue reliance on these forward-looking statements. HBM Healthcare Investments Ltd disclaims any obligation to update these forward-looking statements to reflect future events or developments.